Volume 3, Issue 17 | September 20, 2023

A Phase 3, Single Arm, Open Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women with Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk of Pregnancy

To assess the safety and contraceptive effectiveness of a combination medication of Myfembree and birth control.

A Study to Verify the Clinical Benefit of Aducanumab in Participants with Early Alzheimer's Disease

Looking for subjects between ages 60 years and 85 years to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in CDR-SB score as compared with placebo in participants with early Alzheimer's disease.

The Impact of Auditory Access on the Development of Speech Perception

We are enrolling infants between 1- and 6-months-old for a longitudinal research study on hearing and language development. Compensation Provided!

IMPAACT 2021 RSV Vaccine Study

We are looking for volunteers to participate in a research study to receive a vaccine or placebo to help researchers learn more about how to prevent Respiratory Syncytial Virus (RSV) illness in infants and children. Your child can participate if they have a healthy immune system and have never had an illness caused by RSV.

Reducing Pain and Opioid Use with CBD (ECHO) Study

The ECHO Study is recruiting participants who are interested in using Cannabidiol (CBD) to reduce chronic pain medication use. To qualify for this study you must be interested in reducing your pain symptoms and medications with CBD over a 16 week trial.

Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies

Volunteers are needed for a research study investigating the effects of CBD on alcohol consumption. Participation will span the course of 16 weeks with four in-person visits located on the Anschutz Medical Campus. CBD study medication is provided and will be taken for a total of 12 weeks. 

Bioenergetic Effects of Aging and Menopause (BEAM)

The goal of the BEAM (Bioenergetic Effects of Aging and Menopause) study is to look at how the loss of estrogen and/or the increase in FSH changes cortisol levels, fat gain, and risk of disease in women as they age. At the time of menopause there are changes to stress hormone levels, body composition and metabolism that lead to an increase in the risk of chronic disease. Why this happens is not known, but it is thought to be related to the loss of estrogen and/or the increase in FSH. Postmenopausal women (age range 45-65 years old) who have not had a menstrual cycle in the previous 6 months are eligible for this study. During this study, women who qualify will receive two injections of either a study drug (Degarelix) that suppresses female sex hormone levels or two injections of a placebo (no drug). During the 6 months of drug treatment participants will also be asked to wear a patch on their skin. This patch will contain either estrogen or placebo (no drug).

Morning vs. Evening EXercise (The TIMEX Study)

Research study participants will be randomized to exercise either in the morning or in the evening. Volunteers will receive a free 13-month exercise program and access to the Anschutz Health and Wellness Fitness Center.  

You may qualify for this research study if you meet the following criteria:
•    Adult between 18 and 55 years old 
•    Generally healthy without diabetes or heart disease
•    Non-smoker
•    Not currently exercising more than 150 minutes per week
•    Overweight or Obese (BMI between 25.0 and 40.0 kg/m2)
•    Do not regularly work overnight shifts
Compensation Provided.

The criteria listed above is only a partial list of all the requirements to participate in this research study. Only a clinical research staff member can determine eligibility.

Pathophysiology of Active and Latent Myofascial Trigger Points

Male participants who are generally healthy and either experience or do not experience frequent tension headaches are needed for a research study on muscle trigger points. 

Youth and Young Adult PrEP Study

Did you know that youth and young adults represent the largest proportion of new HIV diagnoses in Colorado? You can help us learn how to prevent HIV among Colorado Youth by getting started on PrEP, the medicine that prevents HIV.

Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

The LUNA Study is recruiting participants who are interested in using Cannabidiol (CBD) to reduce symptoms of their concussion and Traumatic Brain Injury (TBI). It is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve cognition and traumatic brain injury-related symptoms. Main procedures of participation include: cognitive tasks, surveys, blood draws, and drug and pregnancy tests. To qualify for this study you must be interested in reducing your TBI and concussion symptoms (sleep disturbance, pain, anxiety) with CBD. Your participation in this study will be 12 weeks, with 12 weeks of study medication use.

Novel Approaches to Assessing Cannabis Impaired Driving

Researchers at the University of Colorado Anschutz Medical Campus, Colorado School of Public Health, and Injury & Violence Prevention Center want to learn more about how people are affected by cannabis in different ways. We will use a driving simulator to compare the driving performance of adults who use cannabis daily, occasionally or have not recently used cannabis. Receive up to $300 for your time. Experience operating an advanced driving simulator. 

Candidates may be eligible if they:

• Are adults 25 to 55 years old
• Are generally healthy
• Use cannabis daily, occasionally or have not recently used cannabis
• Regularly drive a car or truck 
• Have a driver's license and health insurance